Overview
Compare with Insight Molecular Diagnostics Inc., Anbio Biotechnology or Aspira Women's Health Inc., or pick any stock.
- TickerBMRA on Nasdaq1
- IndustryIn Vitro & In Vivo Diagnostic Substances1
- HeadquartersIrvine, California1
- Incorporated inDE3
- Business address17571 Von Karman Avenue, Irvine, Ca 926143
- Filer categoryNon-accelerated filer, Smaller reporting company3
See how the biggest companies compare on our leaderboards
GmbH in Europe, which supports sales, distribution and other commercial activities in international markets.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Clinical Lab brought in 61% of the revenue BIOMERICA INC broke down this way in fiscal 2026.
Products and services by year
| Products and services | 2025 | 2026 |
|---|---|---|
| Clinical Lab | $3.2M | $2.7M |
| Contract Manufacturing | $1.1M | $891.0K |
| Over-The-Counter | $1.0M | $821.0K |
| Physician?s office | $11.0K | $9.0K |
Regions
North America brought in 33% of the revenue BIOMERICA INC broke down this way in fiscal 2026.
Regions by year
| Regions | 2025 | 2026 |
|---|---|---|
| North America | $1.7M | $1.5M |
| Asia | $1.7M | $1.4M |
| Europe | $1.3M | $1.1M |
| Middle East | $630.0K | $446.0K |
| South America | $8.0K | $15.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue42¢$4.1M
- Research and development8¢$788.0K
- Selling, general and admin50¢$4.9M
- Income tax0¢$23.0K
Out of $4.5M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-05-31 | 2025-05-31 |
|---|---|---|
| Net sales | $4.5M | $5.3M |
| Cost of sales | -$4.1M | -$4.8M |
| Gross profit | $362.0K | $498.0K |
| Selling, general and administrative | $4.9M | $4.6M |
| Research and development | $788.0K | $1.0M |
| Total operating expenses | $5.7M | $5.6M |
| Loss from operations | -$5.3M | -$5.1M |
| Dividend, interest, and other income | $1.2M | $165.0K |
| Unrealized holding gain on equity investment | $335.0K | |
| Total other income | $1.6M | $165.0K |
| Loss before income taxes | -$3.8M | -$5.0M |
| Provision for income taxes | -$23.0K | -$1.0K |
| Net loss | -$3.8M | -$5.0M |
| Basic net loss per common share | -$1.30 | -$2.16 |
| Diluted net loss per common share | -$1.30 | -$2.16 |
| Basic | 2.9M shares | 2.3M shares |
| Diluted | 2.9M shares | 2.3M shares |
| Foreign currency translation adjustment | -$3.0K | -$3.0K |
| Comprehensive loss | -$3.8M | -$5.0M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2026-05-31 | 2025-11-30 | 2025-05-31 | 2024-05-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $1.3M | $2.4M | ||
| Accounts receivable, net | $785.0K | $731.0K | ||
| Inventories, net | $1.7M | $1.5M | ||
| Prepaid expenses and other current assets | $216.0K | $255.0K | ||
| Total current assets | $4.0M | $4.9M | ||
| Property and equipment, net | $78.0K | $135.0K | ||
| Right-of-use assets, net | $1.9M | $429.0K | ||
| Investments | $500.0K | $165.0K | ||
| Intangible assets, net of accumulated amortization of $89,000 and $69,000 as of May 31, 2026 and May 31, 2025, respectively | $209.0K | $228.0K | ||
| Other assets | $83.0K | $113.0K | ||
| Total Assets | $6.8M | $5.9M | ||
| Accounts payable and accrued expenses | $1.2M | $672.0K | ||
| Accrued compensation | $492.0K | $655.0K | ||
| Advances from customers | $83.0K | $55.0K | ||
| Lease liabilities, current portion | $235.0K | $358.0K | ||
| Total current liabilities | $2.5M | $1.7M | ||
| Lease liabilities, net of current portion | $1.6M | $100.0K | ||
| Total Liabilities | $4.1M | $1.8M | ||
| Common stock, $0.08 par value, 25,000,000 shares authorized as of May 31, 2026 and 2025, respectively, and 3,195,263 and 2,546,216 shares issued and outstanding as of May 31, 2026 and 2025, respectively | $255.0K | $203.0K | ||
| Additional paid-in capital | $59.4M | $57.2M | ||
| Accumulated other comprehensive loss | -$108.0K | -$105.0K | ||
| Accumulated deficit | -$56.9M | -$53.2M | ||
| Total shareholders equity | $2.6M | $4.1M | $6.6M | |
| Total Liabilities and Shareholders Equity | $6.8M | $5.9M | ||
| Accumulated amortization | $89.0K | $69.0K | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 4.4M shares | 5.0M shares | 4.4M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.08 | $0.08 | ||
| Common stock, shares authorized | 25.0M shares | 300.0M shares | 25.0M shares | |
| Common stock, shares issued | 3.2M shares | 2.5M shares | ||
| Common stock, shares outstanding | 3.2M shares | 2.5M shares |
| Period ending | 2026-05-31 | 2025-11-30 | 2025-05-31 | 2024-05-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $1.3M | $2.4M | ||
| Accounts receivable, net | $785.0K | $731.0K | ||
| Inventories, net | $1.7M | $1.5M | ||
| Prepaid expenses and other current assets | $216.0K | $255.0K | ||
| Total current assets | $4.0M | $4.9M | ||
| Property and equipment, net | $78.0K | $135.0K | ||
| Right-of-use assets, net | $1.9M | $429.0K | ||
| Investments | $500.0K | $165.0K | ||
| Intangible assets, net of accumulated amortization of $89,000 and $69,000 as of May 31, 2026 and May 31, 2025, respectively | $209.0K | $228.0K | ||
| Other assets | $83.0K | $113.0K | ||
| Total Assets | $6.8M | $5.9M | ||
| Accounts payable and accrued expenses | $1.2M | $672.0K | ||
| Accrued compensation | $492.0K | $655.0K | ||
| Advances from customers | $83.0K | $55.0K | ||
| Lease liabilities, current portion | $235.0K | $358.0K | ||
| Total current liabilities | $2.5M | $1.7M | ||
| Lease liabilities, net of current portion | $1.6M | $100.0K | ||
| Total Liabilities | $4.1M | $1.8M | ||
| Common stock, $0.08 par value, 25,000,000 shares authorized as of May 31, 2026 and 2025, respectively, and 3,195,263 and 2,546,216 shares issued and outstanding as of May 31, 2026 and 2025, respectively | $255.0K | $203.0K | ||
| Additional paid-in capital | $59.4M | $57.2M | ||
| Accumulated other comprehensive loss | -$108.0K | -$105.0K | ||
| Accumulated deficit | -$56.9M | -$53.2M | ||
| Total shareholders equity | $2.6M | $4.1M | $6.6M | |
| Total Liabilities and Shareholders Equity | $6.8M | $5.9M | ||
| Accumulated amortization | $89.0K | $69.0K | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 4.4M shares | 5.0M shares | 4.4M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.08 | $0.08 | ||
| Common stock, shares authorized | 25.0M shares | 300.0M shares | 25.0M shares | |
| Common stock, shares issued | 3.2M shares | 2.5M shares | ||
| Common stock, shares outstanding | 3.2M shares | 2.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-05-31 | 2025-05-31 |
|---|---|---|
| Net loss | -$3.8M | -$5.0M |
| Depreciation and amortization | $77.0K | $87.0K |
| Provision for allowance for credit losses | $12.0K | $8.0K |
| (Recovery) provision for inventory reserves | -$77.0K | $4.0K |
| Share-based compensation | $476.0K | $460.0K |
| Amortization of right-of-use asset | $344.0K | $313.0K |
| Unrealized holding gain on equity investment | -$335.0K | |
| Accounts receivable | -$66.0K | $209.0K |
| Inventories | -$140.0K | $882.0K |
| Prepaid expenses and other current assets | $39.0K | -$17.0K |
| Other assets | $23.0K | $9.0K |
| Accounts payable and accrued expenses | $499.0K | -$467.0K |
| Accrued compensation | -$163.0K | |
| Advances from customers | $28.0K | -$30.0K |
| Reduction in lease liabilities | -$363.0K | -$327.0K |
| Net cash used in operating activities | -$3.4M | -$3.8M |
| Expenditures related to intangibles | -$1.0K | -$37.0K |
| Net cash used in investing activities | -$1.0K | -$37.0K |
| Gross proceeds from sale of common stock | $1.9M | $2.1M |
| Deferred offering costs | -$3.0K | |
| Costs from sale of common stock | -$40.0K | -$44.0K |
| Proceeds from exercise of stock options | $15.0K | |
| Proceeds from secured promissory note payable related party | $500.0K | |
| Net cash provided by financing activities | $2.3M | $2.1M |
| Effect of exchange rate changes on cash | -$3.0K | -$3.0K |
| Net decrease in cash and cash equivalents | -$1.1M | -$1.8M |
| Income taxes | $22.0K | $10.0K |
| Deferred offering costs | $7.0K | $84.0K |
| Right-of-use assets obtained in exchange for operating lease liabilities | $1.8M | |
| Write-off of fully depreciated property and equipment | $14.0K |
No quarter-by-quarter statement was filed.
Corporate structure
BIOMERICA INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of BIOMERICA INC
- BRC Group Holdings, Inc Filed SCHEDULE 13D on BIOMERICA INC, latest Aug 28, 2026
- WASATCH ADVISORS LP Filed SCHEDULE 13G on BIOMERICA INC, latest Feb 11, 2025 (2 filings since Feb 9, 2024)
- Granahan Investment Management, LLC Filed SC 13G/A on BIOMERICA INC, latest Nov 14, 2024 (4 filings since Feb 14, 2022)
- WELLINGTON TRUST Co N A Filed SC 13G/A on BIOMERICA INC, latest Feb 4, 2022
- Wellington Management Company Filed SC 13G/A on BIOMERICA INC, latest Feb 4, 2022
- Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio Filed SC 13G/A on BIOMERICA INC, latest Feb 4, 2022
- BIOMERICA INC Irvine, California
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What BIOMERICA INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated depreciation | $1.5M2 May 31, 2026 | $1.5M2 May 31, 2025 | +2.9% |
| Property and equipment, net | $78.0K2 May 31, 2026 | $135.0K2 May 31, 2025 | −42.2% |
| Operating-lease assets (leased space) | $1.9M2 May 31, 2026 | $429.0K2 May 31, 2025 | +336.6% |
Real estate and locations
Investments
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Intangible assets, net (excluding goodwill) | $209.0K2 May 31, 2026 | $228.0K2 May 31, 2025 | −8.3% |
| Accumulated amortization | $69.0K10 May 31, 2025 | $48.0K10 May 31, 2024 | +43.8% |
| Finite-lived intangibles, net | $209.0K2 May 31, 2026 | $228.0K10 May 31, 2025 | −8.3% |
| Patents, net | $298.0K2 May 31, 2026 | $297.0K2 May 31, 2025 | +0.3% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $1.7M2 May 31, 2026 | $1.5M2 May 31, 2025 | +14.6% |
| Work in process | $868.0K2 May 31, 2026 | $743.0K2 May 31, 2025 | +16.8% |
| Finished goods | $179.0K2 May 31, 2026 | $147.0K2 May 31, 2025 | +21.8% |
Properties, in its own words
On May 31, 2026, we had approximately 22,000 square feet of floor space at our corporate headquarters in Irvine, California, which we have been leasing since 2009. The initial lease term extended through August 31, 2026 and included an additional five-year extension option.
In May 2026, we exercised the additional five-year extension option and entered into a lease extension agreement with the landlord, extending the lease for an additional five-year term from September 1, 2026 through August 31, 2031. The monthly base rent under the extended lease is approximately $28,400. The security deposit is approximately $22,000.
The rest of Item 2
In November 2016, our Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space located in Mexicali, Mexico. We have one 10-year option to renew at the end of the initial lease period. As of May 31, 2026, management determined that exercise of the renewal option was reasonably certain, and we intend to continue to occupy the facility following expiration of the initial lease term. As of the date of this Annual Report, documentation formalizing the renewal had not yet been executed with the landlord. The current rent is approximately $4,300 per month. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. In addition, we lease a small office in Lindau, Germany on a month-to-month basis, which serves as the headquarters of BioEurope GmbH, our German subsidiary.
We believe our space is adequate for our current needs.
Item 2 of the 10-K filed Aug 31, 2026.4
Leadership
Who has led BIOMERICA INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerZacharys Irani Jun 4, 2007 to now14
- ChairAllen Barbieri Dec 31, 2025 to now15
- PresidentFrancis E. Capitanio Jun 2, 2006 to Jan 25, 201816
- Chief financial officerGary Lu Mar 9, 2023 to now17
- Chief financial officerJanet Moore Mar 2, 2015 to Jan 6, 202018
Board members and other officers (16)
- OfficerXiaoxuan Qu Sep 8, 2026 to now19
- Vice chairAllen Barbieri Jun 25, 2021 to now20
- SecretaryJanet Moore Jun 2, 2006 to May 11, 201621
- Cheif Executive OfficerZacharys Irani Jun 2, 2006 to Aug 15, 201622
- Board memberEric Chin Jun 6, 2025 to now23
- Board memberM. Huff Gary Dec 31, 2025 to now24
- Board memberDavid Moatazedi Aug 18, 2023 to now25
- Board memberJohn P. Kenny Aug 29, 2023 to Dec 14, 202326
- Board memberCatherine Coste Sep 3, 2020 to Dec 17, 202427
- Board memberMark A. Sirgo Jul 18, 2016 to Dec 10, 202128
- Board memberJane Emerson May 7, 2007 to Dec 17, 202429
- Board memberJohn Roehm Jul 20, 2007 to Nov 3, 200830
- Board memberAllen Barbieri Jun 2, 2006 to now31
- Board memberFrancis Cano Jun 2, 2006 to Dec 11, 202032
- Board memberJanet Moore Jun 2, 2006 to Jan 6, 202021
- Board memberZacharys Irani Jun 2, 2006 to now22
Timeline
- Oct 15, 20268-K Executive or director change33
- Aug 26, 20268-K Entered a material agreement; Unregistered sale of shares34
- Jun 4, 20268-K Entered a material agreement; New debt or obligation35
- Dec 16, 20258-K Shareholder vote36
- Oct 8, 20258-K Executive or director change; Regulation FD disclosure37
- Jun 6, 20258-K Executive or director change; Regulation FD disclosure38
- Apr 16, 20258-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure39
- Dec 17, 20248-K Shareholder vote40
- Nov 6, 20248-K Listing notice or transfer41
- Jun 28, 20248-K Executive or director change42
- May 10, 20248-K Entered a material agreement; Listing notice or transfer43
- Dec 11, 20238-K Shareholder vote44
- Jun 4, 2007New chief executive Zacharys Irani becomes CEO14
Calendar
When it reported results
- Dec 16, 2021Reported quarterly or annual results45
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
143 filings to the SEC since October 2021: 8 annual reports, 16 quarterly reports, 30 major events, 57 insider forms, 10 large holders, 22 other. The latest 20:
- Oct 15, 202610-Q EDGAR
- Oct 15, 20268-K EDGAR
- Oct 7, 2026EFFECT EDGAR
- Oct 7, 2026EFFECT EDGAR
- Sep 28, 202610-K/A EDGAR
- Sep 24, 2026S-3 EDGAR
- Sep 24, 2026S-3 EDGAR
- Sep 10, 20263 EDGAR
- Sep 8, 20263 EDGAR
- Aug 31, 202610-K EDGAR
- Aug 28, 2026SCHEDULE 13D EDGAR
- Aug 27, 20264 EDGAR
- Aug 27, 20264 EDGAR
- Aug 27, 20264 EDGAR
- Aug 27, 20264 EDGAR
- Aug 27, 20264 EDGAR
- Aug 26, 20268-K EDGAR
- Jun 4, 20268-K EDGAR
- Apr 13, 202610-Q EDGAR
- Feb 27, 2026S-8 EDGAR
The 143 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
18 open-market trades by officers, directors and large owners since October 2021: 18 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | MOATAZEDI DAVIDDirector | Buy | 10,000 | $1.60 | $16.0K | Form 4 |
| Aug 26, 2026 | Chin EricDirector | Buy | 6,250 | $1.60 | $10.0K | Form 4 |
| Aug 26, 2026 | BARBIERI ALLENExecutive Vice Chairman | Buy | 20,000 | $1.60 | $32.0K | Form 4 |
| Aug 26, 2026 | Irani Zackary S.Chief Executive Officer | Buy | 31,250 | $1.60 | $50.0K | Form 4 |
| Aug 20, 2026 | Gary M. HuffDirector | Buy | 31,250 | $1.60 | $50.0K | Form 4 |
| May 25, 2023 | Irani Zackary S.Chief Executive Officer | Buy | 200 | $1.55 | $310 | Form 4 |
| May 24, 2023 | Irani Zackary S.Chief Executive Officer | Buy | 500 | $1.61 | $805 | Form 4 |
| May 12, 2023 | Irani Zackary S.Chief Executive Officer | Buy | 1,700 | $1.17 | $2.0K | Form 4 |
| May 10, 2023 | Irani Zackary S.Chief Executive Officer | Buy | 500 | $1.27 | $635 | Form 4 |
| May 9, 2023 | Irani Zackary S.Chief Executive Officer | Buy | 300 | $1.39 | $417 | Form 4 |
| May 4, 2023 | Irani Zackary S.Chief Executive Officer | Buy | 1,000 | $1.36 | $1.4K | Form 4 |
| Apr 28, 2023 | Irani Zackary S.Chief Executive Officer | Buy | 1,800 | $1.34 | $2.4K | Form 4 |
| Apr 27, 2023 | Irani Zackary S.Chief Executive Officer | Buy | 2,600 | $1.31 | $3.4K | Form 4 |
| Apr 26, 2023 | Irani Zackary S.Chief Executive Officer | Buy | 7,000 | $1.26 | $8.8K | Form 4 |
| Jan 27, 2023 | BARBIERI ALLENExecutive Vice Chairman | Buy | 1,538 | $2.94 | $4.5K | Form 4 |
| Jan 26, 2023 | Coste CatherineDirector | Buy | 2,190 | $2.96 | $6.5K | Form 4 |
| Jan 25, 2023 | Irani Zackary S.Chief Executive Officer | Buy | 1,800 | $2.85 | $5.1K | Form 4 |
| Jan 24, 2023 | Irani Zackary S.Chief Executive Officer | Buy | 2,000 | $2.81 | $5.6K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BRC Group Holdings, IncSCHEDULE 13D, 1 filing Aug 28, 202646
- WASATCH ADVISORS LPSCHEDULE 13G, 2 filings Feb 9, 2024 to Feb 11, 202547
- Granahan Investment Management, LLCSC 13G/A, 4 filings Feb 14, 2022 to Nov 14, 202448
- WELLINGTON TRUST Co N ASC 13G/A, 1 filing Feb 4, 202249
- Wellington Management CompanySC 13G/A, 1 filing Feb 4, 202250
- Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity PortfolioSC 13G/A, 1 filing Feb 4, 202251
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Gary Lu, | 45 | $260.0K | $311.8K52 |
| 2025 | Zackary Irani, | 59 | $122.6K | $201.0K52 |
| 2025 | Allen Barbieri, | 67 | $93.4K | $127.9K52 |
| 2024 | Chief Financial Officer | $260.0K | $385.6K52 | |
| 2024 | Chairman & Chief Executive Officer | $150.0K | $360.1K52 | |
| 2024 | DirectorExecutive Vice Chairman & Secretary | $124.6K | $244.0K52 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Geode Capital Management, LLC | 24,347 | $42.9K | 0.0% | −31,695 |
| BlackRock, Inc. | 18,636 | $32.8K | 0.0% | No change |
| Vanguard Capital Management LLC | 14,514 | $25.5K | 0.0% | No change |
| Jane Street Group, LLC | 12,640 | $22.2K | 0.0% | New |
| LPL Financial LLC | 10,849 | $19.1K | 0.0% | No change |
| UBS Group AG | 6,951 | $12.2K | 0.0% | +6,432 |
| Vanguard Fiduciary Trust Co | 6,613 | $11.6K | 0.0% | No change |
| NewEdge Advisors, LLC | 3,603 | $6.3K | 0.0% | No change |
| Tower Research Capital LLC (TRC) | 238 | $419 | 0.0% | New |
| Hollencrest Capital Management | 200 | $352 | 0.0% | −625 |
| Harbour Investments, Inc. | 125 | $220 | 0.0% | No change |
| Fmr LLC | 83 | $146 | 0.0% | New |
| Hrt Financial LP | 26,374 | $46 | 0.0% | New |
| IFG Advisory, LLC | 25 | $44 | 0.0% | New |
| Larson Financial Group LLC | 12 | $21 | 0.0% | New |
| Barclays PLC | 6 | $11 | 0.0% | New |
| MCF Advisors LLC | 6 | $11 | 0.0% | No change |
| Federation des caisses Desjardins du Quebec | 3 | $5 | 0.0% | New |
| Caitong International Asset Management Co., Ltd | 2 | $4 | 0.0% | New |
| Danske Bank A/s | 1 | $2 | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How BIOMERICA INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARBIOMERICA INC1
- CIK0000073290
- Employer ID (EIN)95-26455734
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
- Incorporated inDelaware4
- Fiscal year endsMay 311
- Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address17571 Von Karman Avenue, Irvine, CA 926141
- Phone94937928751
- Shares outstanding4,598,968 as of Oct 15, 202613
- Public float$6.6M as of Nov 28, 20254
- AuditorHASKELL & WHITE LLP, Irvine, California PCAOB ID 200; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceSep 28, 19951
- Filings604 in all: 4 (208), 8-K (77), 10-Q (55), 10QSB (39), DEF 14A (30), 10-K (18), SC 13G (13), 10KSB (12)1
All 44 form types
4/A (12), NT 10-Q (12), SC 13G/A (12), 3 (11), S-8 (10), CORRESP (8), NT 10-K (8), UPLOAD (8), 424B5 (7), S-3 (6), SC 13D (6), 10QSB/A (5), EFFECT (5), PRE 14A (5), 10KSB/A (4), 5 (4), 10-K/A (3), DEFR14A (3), 10-Q/A (2), 8-K/A (2), PRER14A (2), REGDEX (2), S-3/A (2), 10KSB40 (1), 424B3 (1), 5/A (1), 8-A12B (1), CERTNAS (1), D (1), DEFA14A (1), RW (1), S-4 (1), SB-2 (1), SC 13D/A (1), SCHEDULE 13D (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Aug 31, 2026
Quarterly report (10-Q) Oct 15, 2026
Proxy statement (DEF 14A) Oct 20, 2025
Latest 8-K (8-K) Oct 15, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.08 | BMRA | Nasdaq |
From the cover page of the 10-K filed Aug 31, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks BIOMERICA INC names in Item 1A of its 10-K filed Aug 31, 2026: 33 risks under these headings, as written.4
- RISKS RELATED TO OUR BUSINESS
- We have a history of operating losses and negative cash flows from operations.
- Our operating results may fluctuate adversely as a result of many factors that are outside our control, which could adversely affect our business and the market price of our common stock.
- Fluctuations in our operating results, for any reason, could cause increased operating losses as a result of significant fixed expenses.
- Our revenues have declined, and there is no assurance that we will reverse this trend.
- To remain competitive, we must continue to develop, obtain, and protect our proprietary technologies and intellectual property rights; otherwise, we may lose market share or need to reduce prices as a result of competitors selling technologically superior products that compete with our products or selling products at lower prices.
- To remain competitive, we must expend considerable resources to research new technologies and products and develop new markets, and there is no assurance our efforts to develop new technologies, products, or markets will be successful or such technologies, products, or markets will be commercially viable.
- We maintain a manufacturing plant in Mexico which presents risks to us including risks associated with doing business outside the United States.
- We use hazardous materials in our research and production that may result in unexpected and substantial claims against us relating to handling, storage, or disposal.
- We rely on a limited number of key distributors that account for a substantial majority of our total revenue. The loss of any key distributor or an unsuccessful effort by us to directly distribute our products could lead to reduced sales.
- We face risks relating to our international sales, including inherent economic, political, and regulatory risks, which could impact our financial performance, cause interruptions in our current business operations and impede our growth strategy.
- Tariffs and trade dynamics may affect order timing.
The other 22 risks
- Our results of operations and financial conditions may be adversely affected by the financial soundness of our customers, distributors, and suppliers.
- We extend credit to customers outside the United States which can be difficult to collect.
- If we are not able to manage our growth strategy our operating results may be adversely affected.
- The industry and market segments in which we operate are highly competitive, and intense competition with other providers of diagnostic products may reduce our sales and margins.
- Advances in artificial intelligence and competing diagnostic technologies could reduce demand for our products.
- Intellectual property risks and third-party claims of infringement, misappropriation of proprietary rights, or other claims against us could adversely affect our ability to market our products, require us to redesign our products or attempt to seek licenses from third parties, result in significant costs, and materially adversely affect our operating results.
- We need to continue to raise additional funds to finance our future capital or operating needs, which could have adverse consequences on our operations and the interests of our stockholders.
- Our business and products are highly regulated by various governmental agencies. Our results of operations would be negatively affected by failures or delays in the receipt of regulatory approvals or clearances, the loss of previously received approvals, or other changes to the existing laws and regulations that adversely impact our ability to manufacture and market our products.
- Changes in government policy could adversely affect our business and potential profitability.
- We are subject to numerous government regulations in addition to FDA regulations, and compliance with laws, including changed or new laws, could increase our costs and adversely affect our operations. There is also the risk that our facilities could fail to get the proper licensing at our next inspection or renewal.
- Our total revenue could be affected by third-party reimbursement policies and potential cost constraints.
- Unexpected increases in, or inability to meet, demand for our products could require us to spend considerable resources to meet the demand or harm our reputation and customer relationships if we are unable to meet demand.
- If one or more of our products is claimed to be defective or does not meet the performance criteria we claim in our marketing materials, we could be subject to product recalls, claims of liability, harm to patients or users of our products, or harm to our reputation that could adversely affect our business.
- We are exposed to business risks which, if not covered by insurance, could have an adverse effect on our results of operations. We face potential product liability exposure, and, if claims brought against us are successful, we could incur substantial liabilities.
- Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of studies and trials may not be predictive of future trial results.
- We may rely on third parties to conduct or be part of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to seek or obtain regulatory approval for or commercialize our product candidates.
- Failures in our information technology and storage systems or data security breaches could significantly disrupt our business or force us to expend excessive costs.
- Our business could be negatively affected by the loss of or the inability to hire key personnel.
- Sales of our common stock in the public market could lower the market price for our common stock and adversely impact the trading price of our securities.
- The price of our stock may fluctuate unpredictably in response to factors unrelated to our operating performance.
- Nasdaq’s recently adopted minimum Market Value of Listed Securities requirement of $5 million could result in the suspension and delisting of our common stock from Nasdaq.
- Our ability to use our net operating loss carry forwards in the future may be subject to limitation.
Legal proceedings
From time to time, we are involved in legal proceedings, claims, and litigation arising in the ordinary course of business, which may impact our financial results.
As of May 31, 2026, there were no pending legal proceedings. However, the outcome of any future legal matters, claims, or litigation could potentially have a material adverse effect on our quarterly or annual operating results or cash flows when resolved in subsequent periods. Nonetheless, based on current information, management believes these matters will not have a material adverse effect on our consolidated financial position, results of operations, or cash flows.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARBIOMERICA INC filings on SEC EDGAR
- 2SEC EDGARBIOMERICA INC 10-K for fiscal 2026
- 3SEC EDGARBIOMERICA INC filings on SEC EDGAR
- 4
- 5SEC EDGARBIOMERICA INC 10-K for fiscal 2019
- 6SEC EDGARBIOMERICA INC 10-K for fiscal 2020
- 7SEC EDGARBIOMERICA INC 10-K for fiscal 2021
- 8SEC EDGARBIOMERICA INC 10-K for fiscal 2022
- 9SEC EDGARBIOMERICA INC 10-K for fiscal 2023
- 10SEC EDGARBIOMERICA INC 10-K for fiscal 2024
- 11SEC EDGARBIOMERICA INC 10-Q for fiscal 2025
- 12SEC EDGARBIOMERICA INC 10-Q for fiscal 2026
- 13SEC EDGARBIOMERICA INC 10-Q for fiscal 2026
- 14
- 15SEC EDGARAllen Barbieri, Chair
- 16SEC EDGARFrancis E. Capitanio, President
- 17SEC EDGARGary Lu, Chief financial officer
- 18SEC EDGARJanet Moore, Chief financial officer
- 19SEC EDGARXiaoxuan Qu, Officer
- 20SEC EDGARAllen Barbieri, Vice chair
- 21SEC EDGARJanet Moore, Secretary
- 22
- 23SEC EDGAREric Chin, Board member
- 24SEC EDGARM. Huff Gary, Board member
- 25SEC EDGARDavid Moatazedi, Board member
- 26SEC EDGARJohn P. Kenny, Board member
- 27SEC EDGARCatherine Coste, Board member
- 28SEC EDGARMark A. Sirgo, Board member
- 29SEC EDGARJane Emerson, Board member
- 30SEC EDGARJohn Roehm, Board member
- 31SEC EDGARAllen Barbieri, Board member
- 32SEC EDGARFrancis Cano, Board member
- 33SEC EDGARExecutive or director change
- 34
- 35
- 36SEC EDGARShareholder vote
- 37
- 38
- 39
- 40SEC EDGARShareholder vote
- 41SEC EDGARListing notice or transfer
- 42SEC EDGARExecutive or director change
- 43
- 44SEC EDGARShareholder vote
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52